Bio-Techne has announced a collaboration to distribute Spear Bio’s advanced SPEAR UltraDetect immunoassays worldwide, with an initial focus on the neurology research market. This partnership allows ...

Bio-Techne Corp. TECH has recently entered into a distribution agreement with the U.S. Pharmacopeia (“USP”) to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

Bio-Techne is set to announce its third-quarter earnings next month, and Wall Street expects the company’s EPS to decrease by ...

Bio-Techne Corporation TECH is set to release its first-quarter fiscal 2025 results on Oct. 30, before the opening bell. The medical diagnostic testing provider posted adjusted earnings per share (EPS ...

Bio-Techne develops, manufactures and sells life science reagents, instruments and services for the research, pharmaceutical, diagnostics and bioprocessing markets worldwide. In 2013, Bio-Techne ...

In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors ...

(RTTNews) - Gemini Bioproducts, LLC, a supplier of cell culture reagents and process liquids and healthcare private equity firm BelHealth Investment Partners, LLC announced acquisition of selected ...

Baron Funds, an investment management company, released its “Baron Asset Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. After a strong start to 2025, U.S.